Enalapril: A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Hypertension and Congestive Heart Failure

Drugs

Volumn 31, Issue 3, 1986, Pages 198-248

  Todd, Peter A ^a   Heel, Rennie C ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANGIOTENSIN; ANGIOTENSIN I; ATENOLOL; CAPTOPRIL; ENALAPRIL; ENALAPRIL MALEATE; ENALAPRILAT; FUROSEMIDE; HEMODIALYSIS FLUID; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDOMETACIN; KALLIKREIN; KININ; METHYLDOPA; METOPROLOL; NIFEDIPINE; NORADRENALIN; PLACEBO; POTASSIUM; PROPRANOLOL; PROSTAGLANDIN; SPIRONOLACTONE; SULINDAC; TEPROTIDE; TIMOLOL; TRIAMTERENE; VASOPRESSIN; VERAPAMIL; WARFARIN;

ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; CARDIOVASCULAR SYSTEM; CONGESTIVE HEART FAILURE; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMPARISON; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG TOLERANCE; FATIGUE; HEADACHE; HEART; HUMAN; HYPERTENSION; INTOXICATION; KIDNEY; LEUKOPENIA; NEPHROTOXICITY; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; RESPIRATORY SYSTEM; REVIEW; SKIN TOXICITY; TASTE; THERAPY; VERTIGO;

DRUG INTERACTIONS; ENALAPRIL; HEART FAILURE, CONGESTIVE; HEMODYNAMICS; HUMAN; HYPERTENSION; KALLIKREINS; KINETICS; KININS; PROSTAGLANDINS; RENAL CIRCULATION; RENIN-ANGIOTENSIN SYSTEM;

EID: 0022645133     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198631030-00002     Document Type: Article

References (281)

1. Clinical pharmacology of enalapril
2. Acute and chronic effects of enalapril and MK521 on reflex control and heart rate in normotensive subjects
3. Enalapril with either a ‘very low’ or ‘low’ dose of hydrochlorothiazide is equally effective in essential hypertension
4. A comparative study of enalapril and atenolol in moderate to severe hypertension
5. Safety and efficacy of enalapril in essential hypertension in the elderly
6. New potent inhibitors of angiotensin converting enzymes
7. Rash, eosinophilia, and hyperkalaemia associated with enalapril
8. Role of angiotensin converting enzyme inhibitors in essential and renal hypertension
9. Long-term enalapril/hydrochlorothiazide therapy markedly improves impaired renal function in patients with essential hypertension. Abstract
10. Comparative effects of enalapril vs hydrochlorothiazide on renal function. Abstract
11. Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension
12. Long-term enalapril/hydrochlorothiazide therapy improves renal function in patients with essential hypertension. Abstract
13. Hemodynamic and renal function in essential hypertension during treatment with enalapril
14. Sustained improvement in renal function two years following enalapril/hydrochlorothiazide therapy. Abstract no. 855
15. Attenuation of pressor responses to intracerebroventricular angiotensin I by angiotensin-con-verting enzyme inhibitors and their effects on systemic blood pressure in conscious rats
16. Antihypertensive activity of SCH 31846, a non-sulfhydryl angiotensin-converting enzyme inhibitor
17. Mechanism of deterioration in renal function in patients with renovascular hypertension treated with enalapril
18. Effective dose range of enalapril in mild to moderate essential hypertension
19. Dose-response relationship of enalapril in mild essential hypertension. Abstract no. 1349
20. Comparison of once-a-day and twice-a-day dosage regimens of enalapril (MK-421) in patients with mild hypertension
21. Enalapril (MK-421), an angiotensin converting enzyme (ACE) inhibitor: effects on sympathetic nervous system (SNS) function during treatment of hypertension. Abstract
22. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade
23. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I
24. Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system
25. Plasma renin substrate concentration during chronic propranolol therapy
26. Relation of plasma renin activity to the antihypertensive effect of MK 421 in the rat
27. Reversible acute renal failure during enalapril treatment in patients with chronic glomerulonephritis without renal artery stenosis
28. Selectivity of converting enzyme inhibitors for angiotensin I versus bradykinin hydrolysis reactions. Abstract no. 4260
29. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects
30. Long-term clinical experiences with enalapril in essential hypertension
31. Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril
32. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-l-carboxy-3-phenylpropyl]-L-alanyl]-(1S, 3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid): comparison with captopril and enalaprilat
33. Angiotensin converting enzyme inhibitor, diuretic, and calcium antagonist: a new tritherapy for severe arterial hypertension. Abstract no. 37
34. Acute antihypertensive synergism of angiotensin-converting enzyme inhibitors and diuretics
35. In-vitro response of plasma angiotensin converting enzyme to precursors and active forms of converting enzyme inhibitors
36. Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril
37. A comparative study of captopril and enalapril in patients with severe hypertension
38. The effects of converting enzyme inhibitors on plasma angiotensinogen and plasma aldosterone in sodium-depleted rats
39. Effects of enalapril on clinical state and serum electrolytes in congestive heart failure. Abstract
40. McAlpine H, Semple P, Ball S, Robertson J, Dargie H. First dose hypotension with angiotensin converting enzyme inhibitors in heart failure
41. Angiotensin II-mediated vasoconstriction in chronic congestive heart failure, and response to converting enzyme inhibition
42. Clinical and hemodynamic experience with enalapril in congestive heart failure
43. Covitt AB, Schaer GL, Laragh JH. Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of congestive heart failure
44. Enalapril and hypertension
45. Captopril and MK-421: stability on storage, distribution to the central nervous system, and onset of activity
46. Effect of acute oral administration of captopril and MK-421 on vascular angiotensin converting enzyme activity in the spontaneously hypertensive rat
47. Enalapril in the treatment of hypertension associated with impaired renal function
48. Prolonged hypotension after fever during enalapril treatment
49. Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure
50. Reproduzierbarkeit einer Captopril-induzierten akuten Niereninsuffizienz durch Enalapril
51. Renal glycosuria and azotaemia after enalapril maleate (MK-421)
52. An overview of the clinical pharmacology of enalapril
53. Enalapril worldwide experience
54. Physiological effects of short-term treatment with enalapril in hypertensive patients
55. The angiotensin converting enzyme inhibitor enalapril and its effects on renal function
56. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: a acute and chronic hemodynamic evaluations
57. Successful management of severe congestive cardiac failure with enalapril
58. Acute and chronic hemodynamic effects of enalapril (MK-421) in congestive heart failure
59. Safety and efficacy of enalapril. Summing up the evidence
60. Enalapril (MK-421), a new angiotensin-converting enzyme inhibitor: acute and chronic effects in heart failure
61. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension
62. Editorial. Angiotensin-converting-enzyme inhibitors in treatment of heart failure. Lancet 2: 811–812, 1985b
63. Angiotensin-converting enzyme inhibitors: past, present, and bright future
64. Enalapril in essential hypertension: a comparative study with propranolol
65. Repeated renal failure with captopril
66. A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertension
67. Effects of enalapril, a new converting enzyme inhibitor, in hypertension
68. An appraisal of antihypertensive efficacy and adverse reactions with two drug regimens: enalapril maleate as part of triple therapy compared to conventional triple therapy in moderate to severe hypertension
69. The reversal of left ventricular hypertrophy with control of blood pressure in experimental hypertension
70. The effect of enalapril, a non-thiol converting enzyme inhibitor, on vasoactive factors in hypertension. Abstract
71. Haemodynamic, hormonal and electrolyte effects of enalapril in heart failure
72. Enalapril induced renal impairment in bilateral renal artery stenosis. Abstract
73. Induction of angiotensin-converting enzyme with the ACE inhibitory compound MK-421 in rat lung
74. Cardiac and haemodynamic effects of enalapril
75. Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril)
76. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure
77. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension
78. Acute and chronic effects of enalapril during rest and exercise in congestive heart failure
79. Effect of the angiotensin I converting enzyme inhibitor, MK-421 on experimentally induced drinking. Abstract no. 43
80. Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension
81. Enalaprilat accumulates after chronic enalapril dosing in renal failure. Abstract no. A50
82. Effect of vasodilators on survival in chronic congestive heart failure
83. Regulation of angiotensin converting enzyme
84. Once-a-day enalapril compared with atenolol in hypertension. Abstract no. C50
85. Comparative effects of enalapril, enalaprilic acid and captopril in blocking angiotensin I-induced pressor and dipsogenic responses in spontaneously hypertensive rats
86. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor “MK-421”
87. Captopril and enalapril
88. Efficacy and tolerance of enalapril compared with altizide plus spironolactone in patients with moderate arterial hypertension. Abstract no. 40
89. The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects
90. Duration and action and short-term hormonal responses to enalapril (MK 421) in normal subjects
91. Renin-angiotensin, hemodynamic and renal responses to enalapril with and without hydrochlorothiazide in essential hypertension. Abstract
92. Enalapril: a review of human pharmacology
93. The clinical pharmacology of enalapril
94. Concomitant blockade and activation of the renin-aldosterone system by an angiotensin-converting enzyme inhibitor (MK-421) and hydrochlorothiazide
95. The therapeutic use of a new potassium-sparing diuretic, amiloride, and a converting enzyme inhibitor, MK-421, in preventing hypokalemia associated with primary and secondary hyperaldosteronism
96. Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): a new angiotensin-converting enzyme inhibitor
97. Converting-enzyme inhibitor administration lowers urinary free 19-nor-deoxycorticosterone levels
98. Effect of N-[(S)-l-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
99. Abrupt cessation of enalapril (MK-421) in essential hypertension. Abstract
100. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy
101. Enalapril in essential hypertension
102. Radio-immunoassay for angiotensin converting enzyme inhibitors
103. Effects of age on the pharmacodynamic responses to the angiotensin converting enzyme inhibitors enalapril and enalaprilat
104. The effects of age on the pharmacokinetics and dynamics of the angiotensin converting enzyme inhibitors enalapril and enalaprilat
105. Enalapril in the treatment of hypertension with renal artery stenosis
106. Enalapril in treatment of hypertension with renal artery stenosis
107. Enalapril (MK 421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man
108. In vitro hydrolysis of the angiotensin converting enzyme inhibitor enalapril (MK-421) by plasma and liver
109. Effects of chronic enalapril (MK-421) treatment on the renin-angiotensin system in the sodium deficient rat
110. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney
111. Potentiation of depressor responses to arachidonic acid by angiotensin converting enzyme inhibitors in the rat
112. Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans
113. Bioavailability of enalapril maleate. Abstract no. B14
114. Physiologic adaptation to chronic angiotensin converting enzyme inhibition (ACEI). Abstract no. PL-II
115. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension
116. Angiotensin converting enzyme inhibition by MK421: a potent long acting oral agent
117. Angiotensin converting enzyme inhibition by MK421: a potent long acting oral agent. (Abstract.)
118. Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK421 in essential hypertension
119. Enalapril for severe congestive heart failure
120. Mechanism for hypotensive action of angiotensin converting enzyme inhibitors
121. Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension
122. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition
123. Duration and diurnal variation of the hypotensive effect of enalapril in patients with essential hypertension. Abstract
124. Effect of enalapril at rest, during tilt, static and dynamic exercise in systemic hypertension
125. Perspectives of systolic hypertension
126. Enalapril and lisinopril in renovascular hypertension-antihypertensive and hormonal effects of two new angiotensin-converting enzyme (ACE) inhibitors
127. Acute effects of MK421, a new angiotensin converting enzyme inhibitor, in man
128. Chronic dose pharmacokinetics of enalapril in renal impairment
129. The pharmacokinetic profile of enalaprilat in normal subjects and patients with renal impairment
130. Acute and long-term response to enalapril in congestive failure
131. Sustained haemodynamic effects of enalapril in left ventricular failure
132. Effect of beta blockers and converting enzyme inhibitors on serum lipids. Abstract
133. Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats
134. Effects of a new angiotensin-converting enzyme inhibitor, MK 421, in normal men and patients
135. Enalapril, a rash, and captopril
136. Kinetic and metabolic aspects of enalapril action
137. Hemodynamic results of perorally administered converting enzyme inhibitors in congestive heart failure
138. Enalapril (MK421) activation in man: importance of liver status
139. Effect of enalapril on renin, angiotensin converting enzyme activity, aldosterone and prostaglandins in patients with hypertension
140. Effects of enalapril on timea urinary excretions in healthy adults: a preliminary study
141. Exercise tolerance during treatment of hypertension with enalapril, a new angiotensin converting enzyme (ACE) inhibitor. Abstract
142. Plasma lipid levels with enalapril, a new angiotensin converting enzyme inhibitor, alone and in combination with hydrochlorothiazide. Abstract no. 2625
143. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure
144. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects
145. Systolic and diastolic blood pressure as predictors of coronary heart disease mortality in the Whitehall study
146. Differential effects of atenolol and enalapril on tests of memory during treatment for essential hypertension
147. Protracted effect of converting-enzyme inhibition on the rat’s response to intraarterial bradykinin
148. Enalapril treatment in a patient with impaired renal function and intolerance to captopril
149. Inhibition of converting enzyme in the isolated heart by HOE 498 and MK 421. Abstract no. 135
150. The clinical pharmacology of antihypertensive drugs
151. Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension
152. Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for a role of renin system in normotensive subjects
153. Long-term antihypertensive, metabolic and cellular effects of enalapril
154. Effects of converting enzyme inhibition with enalapril administered to hypertensive insulin-dependent diabetics (IDD). Abstract no. 45
155. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs
156. Tolerance and safety of enalapril
157. Overall tolerance and safety of enalapril
158. Controlled trial of enalapril in congestive heart failure
159. The effect of enalapril on serum prolactin
160. Effects of repeated doses of enalapril on renal function in man
161. Converting enzyme inhibitor therapy limits progressive glomerular injury in rats with renal insufficiency
162. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK 421 (enalapril) and MK 521
163. Enalapril and hydrochlorothiazide (HCTZ) combination therapy: effect on blood pressure (BP), plasma renin activity (PRA) and urinary prostaglandin (PG) excretion. Abstract
164. Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety
165. Cardiac and hormonal effects of enalapril in hypertension
166. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics
167. Enalapril in the treatment of hypertension. Abstract
168. Characterization of the hypotensive and sympathetic response to enalapril. Abstract no. I-D
169. Initial dose of enalapril maleate (MK-421) in renovascular hypertension
170. Comparison of angiotensin converting enzyme inhibitors captopril and MK 421-diacid in guinea pig atria
171. Effects in healthy subjects of a new non-thiol-containing angiotensin-converting enzyme inhibitor, enalapril maleate (MK-421)
172. Regression of left ventricular hypertrophy from systemic hypertension by enalapril
173. Biological properties of the angiotensin-converting enzyme inhibitor cilazapril
174. Absence of cross-reactivity between captopril and enalapril
175. Long term efficacy of enalapril plus hydrochlorothiazide in the treatment of essential hypertension. Abstract no. C29
176. 9 ]-bradykinin in low-renin essential hypertension — before and after treatment with enalapril (MK421)
177. Individualized antihypertensive therapy with enalapril/hydrochlorothiazide: use of 24 hour ambulatory blood pressure monitoring. Abstract no. 146
178. Psychotropic effects of enalapril maleate in normal volunteers
179. Inhibition of angiotensin I converting enzyme (kininase II) with a nonsulfhydryl inhibitor (MK-421) in sodium deficient dogs. Abstract no. 321
180. Antihypertensive effect of enalapril (MK-421) in low renin essential hypertension: role of vasodilator prostaglandins. Abstract
181. Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation
182. Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism and first-pass effect
183. The brain angiotensin system: subcellular localization and interferences with converting enzyme inhibitors
184. New evidence for brain angiotensin and for its role in hypertension
185. Therapeutic implications of hypertension-induced glomerular injury
186. Treatment of unilateral and bilateral renovascular hypertension with converting enzyme inhibitor enalapril. Abstract
187. Enalapril versus triple-drug therapy in the treatment of renovascular hypertension
188. Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives
189. Enalapril and autonomic reflexes and exercise performance
190. Kinetics of inhibition of angiotensin converting enzyme by captopril and by enalapril diacid
191. The renin-angiotensin system in the control of systemic arterial pressure
192. Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats
193. Influence of captopril and enalapril on regional vascular alpha-adrenergic receptor reactivity in SHR
194. MK 421 and prevention of genetic hypertension development in young spontaneously hypertensive rats
195. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure
196. Effect of antihypertensive therapy on left ventricular function and myocardial perfusion at rest and during exercise
197. Resolution of captopril-induced rash after substitution of enalapril
198. Captopril and enalapril: comparative blood pressure and humoral responses in hypertensive patients. Abstract
199. Antihypertensive effects of Cl-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor
200. Peripheral large arteries and the response to antihypertensive treatment
201. Structural changes of large arteries in sustained essential hypertension
202. Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension
203. Enalapril maleate in renal failure. Abstract no. A15
204. Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension
205. A double-blind randomized evaluation of converting enzyme inhibition as the first-step treatment of mild to moderate hypertension
206. 2,and kallikrein excretion in conscious rats
207. Central effects of converting enzyme inhibitors
208. Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension
209. An evaluation of the antihypertensive effect of enalapril with hydrochlorothiazide and methyldopa compared to propranolol with hydrochlorothiazide and hydralazine in patients with moderate to severe hypertension
210. The role of angiotensin II in the development of hypertension and in the maintenance of glomerular filtration rate during 48 hours of renal artery stenosis in conscious dogs
211. Prolonged clinical benefit of enalapril in treatment of congestive cardiac failure. Abstract
212. Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide
213. Enalapril in patients with chronic heart failure: a placebo-controlled, randomised, double-blind study
214. Blood concentration and effect of enalapril on blood pressure, renin angiotensin system and kallikrein kinin system in patients with essential hypertension. Abstract no. 1392
215. Serum concentration and effects of a single dose of enalapril maleate in patients with essential hypertension
216. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension
217. Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects
218. Comparison of oral MK 421 and propranolol in mild to moderate essential hypertension and their effects on arterial and venous vessels of the forearm
219. Effects of acute and chronic angiotensin-converting enzyme inhibition on large arteries in human hypertension
220. Increased renal plasma flow in long-term enalapril treatment of hypertension
221. Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor MK 421 (enalapril) in captopril-intolerant patients
222. Reversible leucopenia associated with angiotensin-converting-enzyme inhibitor MK 421
223. Captopril and enalapril: evaluation of therapeutic efficacy and safety
224. Converting enzyme inhibition in the rat is accompanied by potentiation of inflammation. Abstract no. 143
225. Influence of food on the bioavailability of enalapril
226. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats
227. Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure
228. Antihypertensive activity of N-[(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-a-Pro (MK-421), an orally active converting enzyme inhibitor
229. Enalapril
230. Angiotensin-converting enzyme inhibitor actcvity of SCH 31846, a new non-sulfhydryl inhibitor
231. A comparison of inhibition of angiotensin I conversion by three converting enzyme inhibitors in rats
232. A comparison of the activity of the angiotensin converting enzyme inhibitors SQ 14225, SA 446 and MK 421
233. Leakage of angiotensin converting enzyme inhibitors from the cerebral ventricles into the peripheral circulation in conscious, spoptaneously hypertensive rats
234. A parallel study of enalapril and captopril and 1 year of experience with enalapril treatment in moderate-to-severe essential hypertension
235. Pharmacokinetics of repeated oral doses of enalapril maleate (MK-421) in normal volunteers
236. The physiological disposition and metabolism of enalapril maleate in laboratory animals
237. Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition and metabolism in man
238. Enalapril maleate and a lysine analogue (MK-521): disposition in man
239. Total serum angiotensin converting enzyme activity in rats and dogs after enalapril maleate (MK-421)
240. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl-L-alanyl]-(lS,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats
241. Pharmacology of converting enzyme inhibitors: new aspects
242. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe 498 and MK 421, in spontaneously hypertensive rats
243. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe 498 and MK 421 in spontaneously hypertensive rats
244. Schüll B, Raschler W, Lang RE, Ganten D. Selective activation of the converting enzyme inhibitor MK 421 and comparison of its active diacid form with captopril in different tissues of the rat
245. Radioimmunoassay of blood bradykinin: purification of blood extracts to prevent cross-reaction with endogenous kininogen
246. Haemodynamic effects of enalapril, a new converting enzyme inhibitor, in hypertensive patients
247. A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension
248. Enalapril vs hydrochlorothiazide in hypertension: a multicenter study. Abstract no. 1-C
249. Hemodynamic and humoral responses to enalapril and nifedipine in the rat
250. 2 metabolites after angiotensin converting enzyme inhibition in hypertensive patients
251. Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor
252. “Scalded mouth” caused by angiotensin-converting enzyme inhibitors
253. Antihypertensive effects of enalapril maleate (MK-421) and captopril, alone and with hydrochlorothiazide. Abstract no. 74
254. Comparative antihypertensive effects of enalapril maleate and hydrochlorothiazide, alone and in combination
255. Self poisoning with enalapril
256. The efficacy and safety of enalapril in moderate to severe essential hypertension
257. Chronic effects of enalapril on blood pressure, stroke, plasma renin, urinary electrolytes and PGE: excretion in stroke-prone spontaneously hypertensive rats
258. Initial dose of enalapril in hypertension
259. Effect of enalapril on ventricular arrhythmias in congestive heart failure
260. Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure
261. Enalapril and hydrochlorothiazide in the treatment of essential hypertensive black patients. Abstract
262. Acute and subacute haemodynamic effects of enalapril
263. Evidence for a vasodepressor effect of the angiotensin-converting enzyme inhibitor, MK 421 (enalapril), independent of blockade of angiotensin II formation
264. Enalapril in lowrenin essential hypertension
265. Parallel adrenal and renal abnormalities in young patients with essential hypertension
266. Effect of enalapril (MK-421) and metoprolol (MTP) on blood pressure, converting enzyme, renin, and catecholamines. Abstract no. C30
267. Effects of converting enzyme inhibitors ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart
268. Renal kallikrein-kinin system and the depressor effect of angiotensin converting enzyme inhibitors MK 421, SA 446 and captopril in rats
269. Renal prostaglandin E in the hypotensive mechanism of MK 421 in conscious rats
270. Anti-hypertensive effect of MK-421 in rats: role of the renal kallikrein-kinin system
271. Responses of the kallikrein-kinin system to angiotensin converting enzyme inhibitors in the rat
272. 2 synthesis in vitro: possible mechanism of antihypertensive action. Abstract